Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Benzinga (Video) on MSN22h
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking Mixed Analyst ReactionsAmgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
Hosted on MSN4h
2 Dividend Stocks to Buy Hand Over Fist in NovemberAmgen's potential anti-obesity medicine, MariTide, is currently in phase 2 studies. It looks like one of the more promising ...
Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.
The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...
Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on AAL: Amgen NewsMORE Related Stocks Indices Commodities Currencies ...
Adial's PK study satisfied an FDA requirement for the AD04 Phase 3 trial. Study confirmed AD04 can be taken with or without ...
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space ...
Vivek Ramaswamy reacted to a list of unnecessary government expenditures that included $33 million of government expenditure to run 'Monkey Island' in South Carolina; $549K to a Russian lab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback